Given the emerging potential of CAR-T therapy in nononcological diseases and FAP as a therapeutic target for myocardial fibrosis, we engineered a second-generation FAP-targeted CAR with the 4-1BB costimulatory domain to enhance safety and persistence. Here, FAP is linked to Myocardial fibrosis.